Literature DB >> 23328703

Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic adenocarcinoma tissue.

Elaine Bigelow1, Katherine M Bever, Haiying Xu, Allison Yager, Annie Wu, Janis Taube, Lieping Chen, Elizabeth M Jaffee, Robert A Anders, Lei Zheng.   

Abstract

B7-H1/PD-L1, a member of the B7 family of immune-regulatory cell-surface proteins, plays an important role in the negative regulation of cell-mediated immune responses through its interaction with its receptor, programmed death-1 (PD-1). Overexpression of B7-H1 by tumor cells has been noted in a number of human cancers, including melanoma, glioblastoma, and carcinomas of the lung, breast, colon, ovary, and renal cells, and has been shown to impair anti-tumor T-cell immunity. Recently, B7-H1 expression by pancreatic adenocarcinoma tissues has been identified as a potential prognostic marker. Additionally, blockade of B7-H1 in a mouse model of pancreatic cancer has been shown to produce an anti-tumor response. These data suggest the importance of B7-H1 as a potential therapeutic target. Anti-B7-H1 blockade antibodies are therefore being tested in clinical trials for multiple human solid tumors including melanoma and cancers of lung, colon, kidney, stomach and pancreas. In order to eventually be able to identify the patients who will benefit from B7-H1 targeting therapies, it is critical to investigate the correlation between expression and localization of B7-H1 and patient response to treatment with B7-H1 blockade antibodies. Examining the expression of B7-H1 in human pancreatic adenocarcinoma tissues through immunohistochemistry will give a better understanding of how this co-inhibitory signaling molecule contributes to the suppression of antitumor immunity in the tumor's microenvironment. The anti-B7-H1 monoclonal antibody (clone 5H1) developed by Chen and coworkers has been shown to produce reliable staining results in cryosections of multiple types of human neoplastic tissues, but staining on paraffin-embedded slides had been a challenge until recently. We have developed the B7-H1 staining protocol for paraffin-embedded slides of pancreatic adenocarcinoma tissues. The B7-H1 staining protocol described here produces consistent membranous and cytoplasmic staining of B7-H1 with little background.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23328703      PMCID: PMC3582653          DOI: 10.3791/4059

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  21 in total

1.  B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.

Authors:  H Dong; G Zhu; K Tamada; L Chen
Journal:  Nat Med       Date:  1999-12       Impact factor: 53.440

2.  Clinical significance of B7-H1 and B7-1 expressions in pancreatic carcinoma.

Authors:  Liancai Wang; Qingyong Ma; Xiangli Chen; Kun Guo; Junhui Li; Min Zhang
Journal:  World J Surg       Date:  2010-05       Impact factor: 3.352

Review 3.  Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways.

Authors:  Shengdian Wang; Lieping Chen
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

4.  Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity.

Authors:  Tyler J Curiel; Shuang Wei; Haidong Dong; Xavier Alvarez; Pui Cheng; Peter Mottram; Roman Krzysiek; Keith L Knutson; Ben Daniel; Maria Carla Zimmermann; Odile David; Matthew Burow; Alan Gordon; Nina Dhurandhar; Leann Myers; Ruth Berggren; Akseli Hemminki; Ronald D Alvarez; Dominique Emilie; David T Curiel; Lieping Chen; Weiping Zou
Journal:  Nat Med       Date:  2003-04-21       Impact factor: 53.440

5.  Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape.

Authors:  Janis M Taube; Robert A Anders; Geoffrey D Young; Haiying Xu; Rajni Sharma; Tracee L McMiller; Shuming Chen; Alison P Klein; Drew M Pardoll; Suzanne L Topalian; Lieping Chen
Journal:  Sci Transl Med       Date:  2012-03-28       Impact factor: 17.956

6.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

7.  B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression.

Authors:  Lei Geng; Dongsheng Huang; Junwei Liu; Yigang Qian; Junfang Deng; Donglin Li; Zhenhua Hu; Jian Zhang; Guoping Jiang; Shusen Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2008-03-18       Impact factor: 4.553

8.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.

Authors:  Haidong Dong; Scott E Strome; Diva R Salomao; Hideto Tamura; Fumiya Hirano; Dallas B Flies; Patrick C Roche; Jun Lu; Gefeng Zhu; Koji Tamada; Vanda A Lennon; Esteban Celis; Lieping Chen
Journal:  Nat Med       Date:  2002-06-24       Impact factor: 53.440

9.  Clinical significance and regulation of the costimulatory molecule B7-H1 in pancreatic cancer.

Authors:  Martin Loos; Nathalia A Giese; Jörg Kleeff; Thomas Giese; Matthias M Gaida; Frank Bergmann; Melanie Laschinger; Markus W Büchler; Helmut Friess
Journal:  Cancer Lett       Date:  2008-05-16       Impact factor: 8.679

10.  Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.

Authors:  Rezaul Karim; Ekaterina S Jordanova; Sytse J Piersma; Gemma G Kenter; Lieping Chen; Judith M Boer; Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

View more
  22 in total

1.  Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.

Authors:  Alex B Blair; Lei Zheng
Journal:  Chin Clin Oncol       Date:  2017-06

2.  Prognostic impact of programmed cell death 1 ligand 1 expression in human leukocyte antigen class I-positive hepatocellular carcinoma after curative hepatectomy.

Authors:  Yuichiroh Umemoto; Shinji Okano; Yoshihiro Matsumoto; Hidekazu Nakagawara; Rumi Matono; Shohei Yoshiya; Yo-Ichi Yamashita; Tomoharu Yoshizumi; Toru Ikegami; Yuji Soejima; Mamoru Harada; Shinichi Aishima; Yoshinao Oda; Ken Shirabe; Yoshihiko Maehara
Journal:  J Gastroenterol       Date:  2014-02-08       Impact factor: 7.527

3.  Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.

Authors:  Zhun Wang; Shuanghe Peng; Hui Xie; Linpei Guo; Qiliang Cai; Zhiqun Shang; Ning Jiang; Yuanjie Niu
Journal:  Clin Exp Med       Date:  2018-01-23       Impact factor: 3.984

4.  PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Authors:  Dimitrios Mathios; Jacob Ruzevick; Christopher M Jackson; Haiying Xu; Sagar R Shah; Janis M Taube; Peter C Burger; Edward F McCarthy; Alfredo Quinones-Hinojosa; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2014-10-28       Impact factor: 4.130

Review 5.  Current advances in immunotherapy for pancreatic cancer.

Authors:  Jennifer N Uram; Dung T Le
Journal:  Curr Probl Cancer       Date:  2013-10-08       Impact factor: 3.187

6.  Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Authors:  Alex B Blair; Victoria M Kim; Stephen T Muth; May Tun Saung; Nathalie Lokker; Barbara Blouw; Todd D Armstrong; Elizabeth M Jaffee; Takahiro Tsujikawa; Lisa M Coussens; Jin He; Richard A Burkhart; Christopher L Wolfgang; Lei Zheng
Journal:  Clin Cancer Res       Date:  2019-06-11       Impact factor: 12.531

7.  Diffuse high intensity PD-L1 staining in thymic epithelial tumors.

Authors:  Sukhmani K Padda; Jonathan W Riess; Erich J Schwartz; Lu Tian; Holbrook E Kohrt; Joel W Neal; Robert B West; Heather A Wakelee
Journal:  J Thorac Oncol       Date:  2015-03       Impact factor: 15.609

Review 8.  Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis.

Authors:  Feng Xu; Lingling Xu; Qian Wang; Guangyu An; Guosheng Feng; Fuquan Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

9.  Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.

Authors:  Eric R Lutz; Annie A Wu; Elaine Bigelow; Rajni Sharma; Guanglan Mo; Kevin Soares; Sara Solt; Alvin Dorman; Anthony Wamwea; Allison Yager; Daniel Laheru; Christopher L Wolfgang; Jiang Wang; Ralph H Hruban; Robert A Anders; Elizabeth M Jaffee; Lei Zheng
Journal:  Cancer Immunol Res       Date:  2014-06-18       Impact factor: 11.151

Review 10.  PD-L1 Expression in Lung Cancer.

Authors:  Hui Yu; Theresa A Boyle; Caicun Zhou; David L Rimm; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2016-04-23       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.